Table 4.
Subgroup analysis of patients with adenomyosis stratified by types of infertility and atosiban administration
| Primary infertility (n = 159) | Secondary infertility (n = 177) | |||||
|---|---|---|---|---|---|---|
| Parameters | Atosiban (n = 79) | Control (n = 80) | p value | Atosiban (n = 89) | Control (n = 88) | p value |
| Age (years) | 37.2 ± 4.6 | 37.6 ± 3.6 | 0.471 | 38.6 ± 3.7 | 38.7 ± 3.9 | 0.850 |
| Body mass index (kg/m2) | 23.8 ± 4.0 | 23.4 ± 4.1 | 0.495 | 23.5 ± 3.8 | 24.0 ± 4.5 | 0.490 |
| Infertility duration (years) | 4.3 ± 3.3 | 5.0 ± 3.3 | 0.193 | 5.1 ± 3.1 | 5.6 ± 4.0 | 0.294 |
| Previous IVF attempts (n) | 2.3 ± 2.0 | 3.0 ± 2.5 | 0.054 | 3.4 ± 2.7 | 3.3 ± 2.2 | 0.792 |
| FSH (IU/L) | 5.4 ± 2.8 | 5.1 ± 3.3 | 0.509 | 5.7 ± 3.1 | 5.1 ± 2.5 | 0.183 |
| Anti-Müllerian hormone (ng/ml) | 3.86 ± 3.96 | 3.18 ± 2.81 | 0.214 | 2.92 ± 2.93 | 3.55 ± 2.92 | 0.148 |
| Endometrial thickness (mm) | 11.9 ± 2.3 | 11.7 ± 2.4 | 0.487 | 11.4 ± 2.3 | 11.6 ± 2.0 | 0.611 |
| ET day (%) | 0.106 | 0.932 | ||||
| Day 3 ET | 64.6%(51/79) | 76.3%(61/80) | 56.2%(50/89) | 56.8%(50/88) | ||
| Day 5 ET | 35.4%(28/79) | 23.8%(19/80) | 43.8%(39/89) | 43.2%(38/88) | ||
| At least one top-quality embryos transferred (%) | 82.3%(65/79) | 80.0%(64/80) | 0.714 | 76.4%(68/89) | 77.3%(68/88) | 0.891 |
| Biochemical pregnancy rate (%) | 55.7%(44/79) | 43.8%(35/80) | 0.132 | 61.8%(55/89) | 51.1%(45/88) | 0.153 |
| Clinical pregnancy rate (%) | 51.9%(41/79) | 42.5%(34/80) | 0.235 | 50.6%(45/89) | 51.1%(45/88) | 0.939 |
| Ongoing pregnancy rate (%) | 50.6%(40/79) | 38.8%(31/80) | 0.132 | 43.8%(39/89) | 35.2%(31/88) | 0.242 |
| Live birth rate (%) | 49.4%(39/79) | 37.5%(30/80) | 0.131 | 39.3%(35/89) | 33.0%(29/88) | 0.378 |
| Miscarriage rate (%) | 4.9%(2/41) | 11.8%(4/34) | 0.274 | 22.2%(10/45) | 35.6%(16/45) | 0.163 |
| Early miscarriage rate (%) | 2.4%(1/41) | 8.8%(3/34) | 0.221 | 13.1%(6/45) | 31.1%(14/45) | 0.043 |
| Late miscarriage rate (%) | 2.4%(1/41) | 2.9%(1/34) | 0.893 | 8.9%(4/45) | 4.4%(2/45) | 0.398 |
Data are presented as the mean ± standard deviation and % (n)
IVF, in vitro fertilization; FSH, follicular stimulating hormone; ET, embryo transfer